The Jedell Report: July 2022

DISCLAIMER: NOTHING HEREIN SHOULD BE CONSTRUED AS MEDICAL ADVICE. ONLY A LICENSED PHYSICIAN CAN GIVE YOU ADVICE AND YOU SHOULD CONSULT WITH HIM OR HER. THIS PAPER IS FOR INFORMATIONAL PURPOSES ONLY.

Compiled by David William Jedell Updated January 2, 2025

COVID! Silver nanoparticles as a potential treatment against SARS‐CoV‐2 (COVID-19). Several human coronaviruses (HCoVs) are distinguished by the ability to generate epidemics or pandemics, with their corresponding diseases characterized by severe respiratory illness, such as that which occurs in severe acute respiratory syndrome (SARS‐CoV-2), Middle East respiratory syndrome (MERS‐CoV), and, today, in SARS‐CoV‐2, an outbreak that has struck explosively and uncontrollably beginning in December 2019 and has claimed the lives of more than 1.9 M people worldwide as of January 2021. The development of vaccines has taken one year, which is why it is necessary to investigate whether some already‐existing alternatives that have been successfully developed in recent years can mitigate the pandemic's advance. Silver nanoparticles (AgNPs) have proved effective in antiviral action. Thus, in this review, several in vitro and in vivo studies of the effect of AgNPs on viruses that cause respiratory diseases are analyzed and discussed to promote an understanding of the possible interaction of AgNPs with SARS‐CoV‐2. The study focuses on several in vivo toxicological studies of AgNPs and a dose extrapolation to humans to determine the chief avenue of exposure. It can be concluded that the use of AgNPs as a possible treatment for SARS‐CoV‐2 could be viable, based on comparing the virus' behavior to that of similar viruses in in vivo studies, and that the suggested route of administration in terms of least degree of adverse effects is inhalation. https://pmc.ncbi.nlm.nih.gov/articles/PMC7995207/

Zinc sulfate (1.5 mg/mL) and silver nanoparticles showed comparable potentiated antiviral action with EGCG (50 μM) against the H5N1 avian flu virus (also known as bird flu). They decreased the log titer infection by up to 5.7 and 5.6 fold separately with critical antiviral activity (p<0.01). In most cases, an illustrative relationship was seen when H5N1 was tested with EGCG and various concentrations of zinc sulfate. The EGCG-AgNPs with zinc sulfate were observed to have very strong antiviral activity (p<0.001) against the H5N1 avian influenza virus with a reduction in the log titer of the virus by up to 7.6 times. No cytotoxicity was recognized. The potentiated antiviral activity of EGCG by co-administering it with zinc II and AgNPs indicates potential as a multi-activity novel topical therapeutic agent against H5N1 flue. This mix makes the adaptation of the virus difficult, which helps to reduce infection resistance. https://pubmed.ncbi.nlm.nih.gov/33829450/

Silver nanoparticles with epigallocatechingallate and zinc sulphate significantly inhibits avian influenza A virus H9N2. Avian influenza (AI) has become a disease of great importance for human and animal health. Beside adverse side effects, there is resistance mutation for about all the conventional drugs that target viral proteins. This study aimed to evaluate antiviral activity of silver nanoparticles combined with epigallocatechingallate (EGCG-AgNPs) and co-administered with zinc sulphate (Zn+2) as alternative treatment strategy to control AI H9N2. EGCG conjugated silver nanoparticles (EGCG-AgNPs) were synthesized. Virus propagation was performed using embryonated Specific-Pathogen-Free (SPF) hen's eggs. Viral EID50 titers were determined before and after treatments. The antiviral activity was determined as Log virucidal reduction. A commercial tetrazolium MTS assay kit was used to determine cytotoxicity. Results showed that 50 μM EGCG was the most significant concentration reduced the logEID50/mL of AI H9N2. Co-treatment with zinc sulphate (1.3 mg/mL) increased the EGCG antiviral effect. The most effective antiviral activity was obtained when combined EGCG-AgNPs with zinc sulphate with the greatest virucidal log reduction. No cytotoxic effect in Vero cells was observed among all of these forms at concentrations of interest used in this study. In conclusion, the topical application of EGCG-AgNPs/ZnSO4 demands additional antiviral strategies against H9N2 AI. This combination may prevent virus transmission, inhibit virus replication within neighboring cells and inhibit microbial resistance by making microbial adaptability very difficult. https://pubmed.ncbi.nlm.nih.gov/34182075/

New antiviral drugs and new preventive antiviral strategies are a target of intense scientific interest. Thanks to their peculiar properties, nanomaterials play an important role in this field, and, in particular, among metallic materials, silver nanoparticles were demonstrated to be effective against a wide range of viruses, in addition to having a strong antibacterial effect. Although the mechanism of antiviral action is not completely clarified, silver nanoparticles can directly act on viruses, and on their first steps of interaction with the host cell, depending on several factors, such as size, shape, functionalization and concentration. This review provides an overview of the antiviral properties of silver nanoparticles, along with their demonstrated mechanisms of action and factors mainly influencing their properties. https://pmc.ncbi.nlm.nih.gov/articles/PMC10056906/

Colloidal Silver Experimentally Succesful Against SARS-COVID-2, Mokeypox Viruses and Avian Flu. Colloidal means fine particles in a water solution. (see NIH research studies and reported advers effects below)

Hospital Kills not COVID?

Acute kidney injury in COVID-19 patients receiving remdesivir https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099148/

NIH Virus/Pathogen Research Papers On Colloidal Silver Efficacy

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3244796/

https://pubmed.ncbi.nlm.nih.gov/22024958/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486059/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695609/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3244796/

https://pubmed.ncbi.nlm.nih.gov/22024958/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486059/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695609/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315945/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415816/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167925/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955599/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950764/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404954/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304363/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826769/

https://pubmed.ncbi.nlm.nih.gov/21812950/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375774/

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169222/

Colloidal silver has been a major therapeutic agent in medicine, especially in viral and bacterial infectious diseases

The History Behind the Colloidal Silver Alternative

More Government Scientific Studies

Silver has historically and extensively been used as a broad-spectrum antimicrobial agent. However, the Food and Drug Administration currently does not recognize colloidal silver as a safe and effective antimicrobial agent. The element of silver cannot be patented. The goal of this study was to further evaluate the antimicrobial efficacy of colloidal silver. For bacteria grown under aerobic or anaerobic conditions, significant growth inhibition was observed, although multiple treatments were typically required. For fungal cultures, the effects of ionic colloidal silver varied significantly between different genera. The study data support ionic colloidal silver as a broad-spectrum antimicrobial agent against aerobic and anaerobic bacteria, while having a more limited and specific spectrum of activity against fungi. https://www.ncbi.nlm.nih.gov/m/pubmed/23017226/

Silver nanoparticles (AgNPs) have been used as antibacterial, antifungal, antiviral, anti-inflammtory, and antiangiogenic due to its unique properties such as physical, chemical, and biological properties. The present study was aimed to investigate antibacterial and anti-biofilm activities of silver nanoparticles alone and in combination with conventional antibiotics against various human pathogenic bacteria. Furthermore, the antibacterial and anti-biofilm activity of antibiotics or AgNPs, or combinations of AgNPs with an antibiotic was evaluated using a series of assays: such as in vitro killing assay, disc diffusion assay, biofilm inhibition, and reactive oxygen species generation in Pseudomonas aeruginosa, Shigella flexneri, Staphylococcus aureus, and Streptococcus pneumonia. The results suggest that, in combination with antibiotics, there were significant antimicrobial and anti-biofilm effects at lowest concentration of AgNPs using a novel plant extract of A. cobbe, otherwise sublethal concentrations of the antibiotics. The significant enhancing effects were observed for ampicillin and vancomycin against Gram-negative and Gram-positive bacteria, respectively. These data suggest that combining antibiotics and biogenic AgNPs can be used therapeutically for the treatment of infectious diseases caused by bacteria. This study presented evidence of antibacterial and anti-biofilm effects of A. cobbe-mediated synthesis of AgNPs and their enhanced capacity against various human pathogenic bacteria. These results suggest that AgNPs could be used as an adjuvant for the treatment of infectious diseases. https://www.ncbi.nlm.nih.gov/pubmed/25136281

"The most critical physico-chemical parameters that affect the antimicrobial potential of AgNPs include size, shape, surface charge, concentration and colloidal state. AgNPs exhibits their antimicrobial potential through multifaceted mechanisms. AgNPs adhesion to microbial cells, penetration inside the cells, ROS and free radical generation, and modulation of microbial signal transduction pathways have been recognized as the most prominent modes of antimicrobial action," see, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5110546/

Open VAERS COVID Vaccine Adverse Event Reports, see, https://openvaers.com/covid-data

1,640,416 Reports Through May 31, 2024 (Extrapolated From Official USA Data)

34,647 Deaths

216,757 Hospitalizations

154,810 Urgent Care

243,814 Doctor Office Visits

10,834 Anaphalaxis

17,759 Bell's Palsy

5,139 Miscarriages

21,741 Heart Attacks

28,445 Myocarditis/Pericarditis

71,005 Permanently Disabled

9,218 Thrombcytopenia/Low Platelet

40,002 Life Threatening

46,899 Severe Allergic Reaction

16,147 Shingles

Copyright © 2025 by David William Jedell

Email: d.w.jedell@gmail.com

The Jedell Report

Saturday, July 23, 2022

Multi Video Edification of Airline Incidents Excellently Explained for Passengers as well as for Pilots, Crew, Attendants, Maintenance, Manufacturers

Silver Nanoparticles: NIH Studies Confirm Colloidal Silver Apparently Kills COVID Virus, Monkey Pox and Bird Flu. "Destroys Viral and Bacterial Pathogens"

Apparent Arson-Caused Wildfire Smoke and Heat Affecting Millions of Americans. Virtually Proven Here that Wildfires are Not Caused by Climate Change, but Wildfires Actually Cause Hot Weather that Heats the Earth's Atmosphere

Report Abuse